| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hawaii | 49 | 2022 | 1878 | 1.740 |
Why?
|
| Heart Failure | 11 | 2017 | 230 | 1.640 |
Why?
|
| Diabetes Mellitus | 10 | 2023 | 465 | 1.360 |
Why?
|
| Health Status Disparities | 9 | 2020 | 583 | 1.220 |
Why?
|
| Echocardiography | 8 | 2017 | 144 | 1.050 |
Why?
|
| Methamphetamine | 6 | 2015 | 155 | 1.040 |
Why?
|
| Cross Infection | 2 | 2016 | 38 | 1.030 |
Why?
|
| Humans | 101 | 2023 | 34853 | 1.010 |
Why?
|
| Guideline Adherence | 5 | 2013 | 82 | 1.000 |
Why?
|
| Middle Aged | 66 | 2021 | 9642 | 0.990 |
Why?
|
| Hospitalization | 12 | 2022 | 370 | 0.940 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2023 | 48 | 0.940 |
Why?
|
| Central Nervous System Stimulants | 4 | 2015 | 165 | 0.930 |
Why?
|
| Cardiovascular Diseases | 12 | 2021 | 628 | 0.890 |
Why?
|
| Bacteremia | 2 | 2016 | 31 | 0.880 |
Why?
|
| Therapeutic Equipoise | 1 | 2021 | 1 | 0.800 |
Why?
|
| Adult | 51 | 2021 | 11034 | 0.770 |
Why?
|
| Male | 69 | 2021 | 18870 | 0.750 |
Why?
|
| Hypertension | 9 | 2023 | 770 | 0.740 |
Why?
|
| Embolism, Paradoxical | 1 | 2019 | 3 | 0.700 |
Why?
|
| Foramen Ovale, Patent | 1 | 2019 | 5 | 0.700 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 355 | 0.700 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 14 | 0.690 |
Why?
|
| Aged | 37 | 2021 | 6448 | 0.690 |
Why?
|
| Stroke Volume | 5 | 2014 | 97 | 0.690 |
Why?
|
| Female | 61 | 2023 | 19873 | 0.670 |
Why?
|
| Cerebral Hemorrhage | 3 | 2015 | 103 | 0.670 |
Why?
|
| Dancing | 5 | 2017 | 19 | 0.660 |
Why?
|
| Heart Diseases | 5 | 2021 | 99 | 0.610 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 42 | 0.580 |
Why?
|
| Coronary Disease | 5 | 2020 | 113 | 0.560 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2014 | 63 | 0.560 |
Why?
|
| Medicare | 2 | 2017 | 188 | 0.560 |
Why?
|
| Legislation, Drug | 1 | 2015 | 5 | 0.550 |
Why?
|
| Awards and Prizes | 2 | 2018 | 27 | 0.550 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 58 | 0.550 |
Why?
|
| Thromboembolism | 4 | 2006 | 14 | 0.540 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 64 | 0.540 |
Why?
|
| Public Health | 1 | 2019 | 348 | 0.520 |
Why?
|
| Community-Based Participatory Research | 2 | 2019 | 292 | 0.510 |
Why?
|
| Healthcare Disparities | 4 | 2020 | 446 | 0.490 |
Why?
|
| Cardiography, Impedance | 2 | 2013 | 5 | 0.490 |
Why?
|
| Culture | 3 | 2014 | 162 | 0.490 |
Why?
|
| Patient Isolation | 1 | 2013 | 1 | 0.480 |
Why?
|
| Genetic Research | 1 | 2013 | 6 | 0.480 |
Why?
|
| Prevalence | 11 | 2015 | 1425 | 0.480 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2013 | 16 | 0.470 |
Why?
|
| Vascular Resistance | 1 | 2013 | 32 | 0.460 |
Why?
|
| Risk Factors | 20 | 2020 | 3414 | 0.460 |
Why?
|
| Retrospective Studies | 14 | 2017 | 1961 | 0.460 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 47 | 0.460 |
Why?
|
| Endocarditis | 3 | 2002 | 11 | 0.450 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2016 | 36 | 0.440 |
Why?
|
| HIV Infections | 9 | 2023 | 2207 | 0.440 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 2333 | 0.440 |
Why?
|
| Stroke | 2 | 2013 | 274 | 0.430 |
Why?
|
| Health Services Accessibility | 5 | 2015 | 531 | 0.430 |
Why?
|
| Registries | 2 | 2019 | 330 | 0.430 |
Why?
|
| Fibrinolytic Agents | 3 | 2005 | 23 | 0.400 |
Why?
|
| Hospitals | 2 | 2022 | 86 | 0.400 |
Why?
|
| Hospital Mortality | 3 | 2023 | 183 | 0.390 |
Why?
|
| Indians, North American | 1 | 2013 | 145 | 0.390 |
Why?
|
| Brain Ischemia | 1 | 2013 | 179 | 0.390 |
Why?
|
| Japan | 13 | 2016 | 296 | 0.380 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 40 | 0.370 |
Why?
|
| Schools, Medical | 1 | 2011 | 192 | 0.340 |
Why?
|
| Venous Thrombosis | 2 | 2005 | 27 | 0.340 |
Why?
|
| United States | 14 | 2019 | 3894 | 0.340 |
Why?
|
| Comorbidity | 4 | 2023 | 606 | 0.340 |
Why?
|
| Patient Compliance | 2 | 2007 | 202 | 0.320 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 132 | 0.320 |
Why?
|
| Education | 2 | 2019 | 48 | 0.310 |
Why?
|
| Endocarditis, Bacterial | 1 | 2007 | 4 | 0.310 |
Why?
|
| Monocytes | 3 | 2014 | 258 | 0.310 |
Why?
|
| Interleukin-6 | 2 | 2021 | 140 | 0.300 |
Why?
|
| Young Adult | 9 | 2020 | 4012 | 0.300 |
Why?
|
| Dementia | 2 | 2020 | 133 | 0.290 |
Why?
|
| Family | 1 | 2008 | 162 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 32 | 0.280 |
Why?
|
| Dental Caries | 1 | 2007 | 54 | 0.280 |
Why?
|
| Cultural Characteristics | 2 | 2017 | 119 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 790 | 0.280 |
Why?
|
| Drug Utilization Review | 1 | 2005 | 7 | 0.280 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2005 | 13 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 12 | 0.270 |
Why?
|
| Myocardial Infarction | 4 | 2015 | 221 | 0.270 |
Why?
|
| Chemoprevention | 1 | 2005 | 34 | 0.270 |
Why?
|
| Caregivers | 1 | 2008 | 167 | 0.270 |
Why?
|
| Cross-Sectional Studies | 13 | 2020 | 2561 | 0.270 |
Why?
|
| Hip Fractures | 1 | 2005 | 26 | 0.270 |
Why?
|
| Attitude to Health | 1 | 2008 | 311 | 0.260 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 205 | 0.260 |
Why?
|
| Health Literacy | 2 | 2021 | 100 | 0.260 |
Why?
|
| Age Factors | 7 | 2015 | 1007 | 0.250 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 118 | 0.250 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 284 | 0.250 |
Why?
|
| Odds Ratio | 6 | 2021 | 517 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2005 | 206 | 0.250 |
Why?
|
| Respiratory Rate | 2 | 2017 | 10 | 0.240 |
Why?
|
| Pregnancy | 4 | 2021 | 1503 | 0.240 |
Why?
|
| Anti-Retroviral Agents | 3 | 2013 | 139 | 0.240 |
Why?
|
| Granulocytes | 1 | 2023 | 28 | 0.240 |
Why?
|
| Cardiology | 2 | 2006 | 16 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 3 | 2006 | 187 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2014 | 1422 | 0.220 |
Why?
|
| Blood Pressure | 4 | 2023 | 613 | 0.220 |
Why?
|
| Atrial Fibrillation | 2 | 2002 | 105 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 4 | 2004 | 231 | 0.210 |
Why?
|
| Interviews as Topic | 4 | 2017 | 356 | 0.210 |
Why?
|
| Coronary Artery Disease | 2 | 2013 | 147 | 0.210 |
Why?
|
| Aortic Diseases | 2 | 2012 | 26 | 0.210 |
Why?
|
| Allergy and Immunology | 1 | 2001 | 11 | 0.210 |
Why?
|
| Physicians, Family | 1 | 2001 | 19 | 0.210 |
Why?
|
| Food Supply | 1 | 2023 | 99 | 0.210 |
Why?
|
| Obesity | 1 | 2010 | 965 | 0.210 |
Why?
|
| Academic Medical Centers | 1 | 2001 | 54 | 0.210 |
Why?
|
| Chloroquine | 1 | 2021 | 19 | 0.200 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 15 | 0.200 |
Why?
|
| Health Status | 3 | 2014 | 356 | 0.200 |
Why?
|
| Education, Medical | 1 | 2001 | 97 | 0.190 |
Why?
|
| Sex Factors | 8 | 2020 | 859 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 528 | 0.190 |
Why?
|
| Atrial Appendage | 1 | 1999 | 4 | 0.180 |
Why?
|
| Cardiomyopathies | 2 | 2013 | 55 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 99 | 0.180 |
Why?
|
| Heart Rate | 2 | 2017 | 248 | 0.180 |
Why?
|
| Trust | 2 | 2013 | 119 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 195 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2019 | 65 | 0.170 |
Why?
|
| Preventive Medicine | 1 | 2018 | 15 | 0.170 |
Why?
|
| Risk Assessment | 6 | 2013 | 727 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2016 | 271 | 0.160 |
Why?
|
| Writing | 1 | 2018 | 33 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 35 | 0.160 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 186 | 0.160 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.160 |
Why?
|
| Adolescent | 6 | 2018 | 5035 | 0.160 |
Why?
|
| Blood Flow Velocity | 2 | 2013 | 63 | 0.160 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 570 | 0.160 |
Why?
|
| Waiting Lists | 1 | 2018 | 33 | 0.160 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2017 | 4 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 17 | 0.160 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 147 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2018 | 30 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2018 | 74 | 0.150 |
Why?
|
| Drug Costs | 1 | 2017 | 28 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 59 | 0.150 |
Why?
|
| Carotid Arteries | 2 | 2014 | 29 | 0.150 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2016 | 5 | 0.150 |
Why?
|
| Cholesterol | 2 | 2015 | 194 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2002 | 19 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 233 | 0.150 |
Why?
|
| Lipoproteins | 2 | 2014 | 61 | 0.150 |
Why?
|
| Diet | 4 | 2023 | 747 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 254 | 0.150 |
Why?
|
| Housing | 1 | 2017 | 54 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 68 | 0.140 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 159 | 0.140 |
Why?
|
| Adiponectin | 1 | 2016 | 52 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 77 | 0.140 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2009 | 26 | 0.140 |
Why?
|
| Ribavirin | 1 | 2016 | 17 | 0.140 |
Why?
|
| Arteries | 2 | 2014 | 67 | 0.140 |
Why?
|
| HIV-1 | 2 | 2013 | 678 | 0.140 |
Why?
|
| Trans Fatty Acids | 1 | 2016 | 5 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2017 | 119 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2014 | 88 | 0.140 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hepacivirus | 1 | 2016 | 59 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 39 | 0.140 |
Why?
|
| Taxes | 1 | 2015 | 13 | 0.140 |
Why?
|
| Blood Glucose | 3 | 2014 | 333 | 0.140 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2015 | 6 | 0.140 |
Why?
|
| Risk Adjustment | 1 | 2015 | 17 | 0.130 |
Why?
|
| Atherosclerosis | 2 | 2014 | 131 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2014 | 775 | 0.130 |
Why?
|
| Politics | 1 | 2015 | 35 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1426 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2021 | 1353 | 0.130 |
Why?
|
| Logistic Models | 2 | 2009 | 894 | 0.130 |
Why?
|
| Insulin Resistance | 2 | 2014 | 177 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 371 | 0.130 |
Why?
|
| Aorta | 2 | 2014 | 161 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 325 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2004 | 46 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2016 | 148 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 43 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 61 | 0.130 |
Why?
|
| Minority Groups | 1 | 2019 | 537 | 0.130 |
Why?
|
| Lacerations | 1 | 2014 | 6 | 0.120 |
Why?
|
| Obstetric Labor Complications | 1 | 2014 | 8 | 0.120 |
Why?
|
| Perineum | 1 | 2014 | 10 | 0.120 |
Why?
|
| Metabolic Equivalent | 1 | 2013 | 4 | 0.120 |
Why?
|
| Pennsylvania | 4 | 2016 | 41 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2015 | 159 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 13 | 0.120 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 38 | 0.120 |
Why?
|
| Resuscitation Orders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Plasma | 1 | 2013 | 29 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 142 | 0.120 |
Why?
|
| Sputum | 1 | 2013 | 16 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2013 | 6 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2006 | 97 | 0.120 |
Why?
|
| Pregnancy Trimesters | 1 | 2013 | 15 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 66 | 0.120 |
Why?
|
| Focus Groups | 2 | 2019 | 307 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 881 | 0.110 |
Why?
|
| Social Support | 3 | 2014 | 356 | 0.110 |
Why?
|
| Time Factors | 3 | 2013 | 1681 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 82 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 56 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2013 | 160 | 0.110 |
Why?
|
| Inflammation | 2 | 2014 | 577 | 0.110 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 36 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2020 | 393 | 0.110 |
Why?
|
| Asia | 2 | 2016 | 74 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 206 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 964 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2011 | 23 | 0.100 |
Why?
|
| Ventricular Function, Left | 2 | 2009 | 104 | 0.100 |
Why?
|
| Fish Oils | 1 | 2011 | 12 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2016 | 1349 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2011 | 30 | 0.100 |
Why?
|
| Calcinosis | 1 | 2012 | 56 | 0.100 |
Why?
|
| Mitochondria | 1 | 2014 | 454 | 0.100 |
Why?
|
| Organizational Objectives | 1 | 2011 | 30 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 393 | 0.100 |
Why?
|
| Calcium | 1 | 2013 | 445 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 296 | 0.090 |
Why?
|
| Outpatients | 1 | 2010 | 33 | 0.090 |
Why?
|
| Benchmarking | 1 | 2010 | 27 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 231 | 0.090 |
Why?
|
| Niacin | 1 | 2010 | 23 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 35 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 42 | 0.090 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 2009 | 2 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 87 | 0.090 |
Why?
|
| Child | 3 | 2023 | 2875 | 0.090 |
Why?
|
| Vasodilation | 1 | 2010 | 65 | 0.090 |
Why?
|
| Health Promotion | 1 | 2015 | 588 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 142 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2010 | 212 | 0.090 |
Why?
|
| Posture | 1 | 2009 | 57 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 176 | 0.090 |
Why?
|
| Single Person | 1 | 2009 | 4 | 0.090 |
Why?
|
| Divorce | 1 | 2009 | 5 | 0.090 |
Why?
|
| Doppler Effect | 1 | 2009 | 1 | 0.090 |
Why?
|
| Radar | 1 | 2009 | 1 | 0.090 |
Why?
|
| Prognosis | 2 | 2013 | 707 | 0.090 |
Why?
|
| Republic of Korea | 3 | 2014 | 103 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 874 | 0.090 |
Why?
|
| Exercise | 1 | 2014 | 524 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 35 | 0.080 |
Why?
|
| Smoking | 2 | 2014 | 903 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 222 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 217 | 0.080 |
Why?
|
| Sleep | 1 | 2009 | 122 | 0.080 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 14 | 0.080 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 36 | 0.080 |
Why?
|
| Samoa | 1 | 2008 | 17 | 0.080 |
Why?
|
| Medicine, Traditional | 1 | 2008 | 20 | 0.080 |
Why?
|
| Mental Health | 3 | 2017 | 270 | 0.080 |
Why?
|
| Electrocardiography | 3 | 2010 | 154 | 0.080 |
Why?
|
| Communication Barriers | 1 | 2008 | 53 | 0.080 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 8 | 0.080 |
Why?
|
| Linear Models | 3 | 2013 | 253 | 0.080 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 46 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2007 | 100 | 0.070 |
Why?
|
| Incidence | 4 | 2013 | 882 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 94 | 0.070 |
Why?
|
| Cultural Competency | 1 | 2008 | 120 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 8 | 0.070 |
Why?
|
| Self Care | 1 | 2008 | 150 | 0.070 |
Why?
|
| Disease Progression | 2 | 2021 | 580 | 0.070 |
Why?
|
| Mastectomy, Segmental | 1 | 2006 | 18 | 0.070 |
Why?
|
| Premedication | 1 | 2006 | 4 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2006 | 6 | 0.070 |
Why?
|
| Risk | 2 | 2013 | 256 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 207 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 1 | 2006 | 17 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2005 | 38 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 269 | 0.070 |
Why?
|
| American Heart Association | 2 | 2002 | 17 | 0.070 |
Why?
|
| Pacific Islands | 1 | 2005 | 115 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 60 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2004 | 8 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 358 | 0.070 |
Why?
|
| Women's Health Services | 1 | 2004 | 10 | 0.070 |
Why?
|
| Angina Pectoris | 1 | 2004 | 18 | 0.060 |
Why?
|
| Program Evaluation | 2 | 2017 | 316 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 178 | 0.060 |
Why?
|
| Genotype | 2 | 2016 | 641 | 0.060 |
Why?
|
| Ankle Brachial Index | 2 | 2014 | 16 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 30 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2002 | 12 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 54 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 281 | 0.060 |
Why?
|
| Neutrophils | 1 | 2023 | 124 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 638 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2002 | 7 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 608 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 424 | 0.050 |
Why?
|
| Altitude Sickness | 1 | 2002 | 2 | 0.050 |
Why?
|
| Ginkgo biloba | 1 | 2002 | 3 | 0.050 |
Why?
|
| Brachial Artery | 2 | 2014 | 31 | 0.050 |
Why?
|
| Histones | 1 | 2023 | 177 | 0.050 |
Why?
|
| Warfarin | 1 | 2002 | 59 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 26 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 37 | 0.050 |
Why?
|
| Albumins | 1 | 2001 | 24 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2002 | 62 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2001 | 41 | 0.050 |
Why?
|
| International Cooperation | 1 | 2021 | 44 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2021 | 80 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2001 | 19 | 0.050 |
Why?
|
| Exercise Test | 1 | 2001 | 68 | 0.050 |
Why?
|
| Contrast Media | 1 | 2001 | 95 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 628 | 0.050 |
Why?
|
| Cause of Death | 1 | 2021 | 154 | 0.050 |
Why?
|
| Patient Participation | 1 | 2021 | 68 | 0.050 |
Why?
|
| Acute Disease | 3 | 2004 | 141 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2001 | 528 | 0.050 |
Why?
|
| Procainamide | 1 | 1999 | 1 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1999 | 11 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1999 | 12 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 58 | 0.050 |
Why?
|
| Substance-Related Disorders | 2 | 2007 | 685 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 841 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2020 | 76 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 288 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 211 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 90 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2002 | 250 | 0.040 |
Why?
|
| Georgia | 1 | 2019 | 155 | 0.040 |
Why?
|
| Aging | 1 | 2023 | 639 | 0.040 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 4 | 0.040 |
Why?
|
| Stethoscopes | 1 | 2017 | 1 | 0.040 |
Why?
|
| Community Health Services | 1 | 2019 | 175 | 0.040 |
Why?
|
| Lovastatin | 1 | 2017 | 10 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2017 | 34 | 0.040 |
Why?
|
| Decision Making | 1 | 1999 | 189 | 0.040 |
Why?
|
| Reference Values | 1 | 2017 | 204 | 0.040 |
Why?
|
| Simvastatin | 1 | 2017 | 28 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2017 | 59 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 9 | 0.040 |
Why?
|
| Water Supply | 1 | 2017 | 54 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2016 | 15 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 53 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 51 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 5 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 12 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 2 | 0.040 |
Why?
|
| Spiritual Therapies | 1 | 2014 | 9 | 0.030 |
Why?
|
| Medical Audit | 2 | 2004 | 24 | 0.030 |
Why?
|
| Longevity | 1 | 2016 | 143 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 133 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 7 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2014 | 26 | 0.030 |
Why?
|
| Plethysmography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2014 | 11 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 200 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2014 | 53 | 0.030 |
Why?
|
| Philippines | 1 | 2014 | 72 | 0.030 |
Why?
|
| Micronesia | 1 | 2014 | 87 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 27 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2013 | 48 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 193 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 84 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 98 | 0.030 |
Why?
|
| China | 1 | 2014 | 178 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 224 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 213 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 148 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 129 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2016 | 285 | 0.030 |
Why?
|
| Spleen | 1 | 2013 | 192 | 0.030 |
Why?
|
| Compliance | 1 | 2012 | 9 | 0.030 |
Why?
|
| Aortography | 1 | 2012 | 10 | 0.030 |
Why?
|
| Radiography | 1 | 2012 | 75 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2012 | 15 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 146 | 0.030 |
Why?
|
| Life Style | 1 | 2014 | 288 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 878 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 650 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2011 | 115 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 447 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 73 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 55 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 901 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 490 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 57 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 468 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 459 | 0.020 |
Why?
|
| Polysomnography | 1 | 2009 | 30 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 50 | 0.020 |
Why?
|
| Respiratory System | 1 | 2009 | 21 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 185 | 0.020 |
Why?
|
| Heart Atria | 1 | 2009 | 27 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 115 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 219 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 292 | 0.020 |
Why?
|
| Tunica Media | 1 | 2008 | 14 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2008 | 21 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2009 | 121 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2008 | 114 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2006 | 5 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2006 | 7 | 0.020 |
Why?
|
| Heparin | 1 | 2006 | 34 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2006 | 22 | 0.020 |
Why?
|
| Aortic Valve | 1 | 2006 | 25 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 151 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2006 | 98 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2005 | 24 | 0.020 |
Why?
|
| Colon | 1 | 2006 | 98 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 1268 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 64 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2004 | 92 | 0.020 |
Why?
|
| Aspirin | 1 | 2004 | 45 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1056 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 2 | 0.010 |
Why?
|
| Hospital Charges | 1 | 2003 | 13 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 22 | 0.010 |
Why?
|
| Stents | 1 | 2003 | 59 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 43 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 69 | 0.010 |
Why?
|
| Mountaineering | 1 | 2002 | 2 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2002 | 110 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 269 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 14307 | 0.010 |
Why?
|